Mivacurium

Mivacurium: Overview

Mivacurium is a short-acting non-depolarizing neuromuscular blocking agent belonging to the bisbenzylisoquinolinium chemical class. It is administered intravenously as an adjunct to general anesthesia to relax skeletal muscles, facilitate endotracheal intubation, and assist mechanical ventilation during surgical procedures.

What Is Mivacurium & How Does It Work?

Mivacurium acts as a short-acting non-depolarizing muscle relaxant by targeting nerve-to-muscle communication. At the neuromuscular junction, it binds competitively to cholinergic receptors on the motor end-plate, specifically acting as an antagonist at the neuronal acetylcholine receptor subunit alpha-2. By blocking acetylcholine from binding to these receptors, Mivacurium prevents electrical depolarization of the muscle membrane, which inhibits nerve impulse transmission and causes flaccid paralysis of skeletal muscles. Because Mivacurium is rapidly hydrolyzed by plasma cholinesterase (pseudocholinesterase), its neuromuscular blockade is short-lived and can be promptly reversed using acetylcholinesterase inhibitors like neostigmine when clinically needed.

Is Mivacurium FDA Approved?

Mivacurium received official prescription approval from the United States Food and Drug Administration in January 1992 under the brand name Mivacron. In a General Medicine and surgical care setting, anesthesiologists and critical care specialists utilize Mivacurium for both inpatient and outpatient operative procedures requiring short-duration muscle relaxation.

What Is Mivacurium Used For?

• Facilitating endotracheal intubation in adult and pediatric patients undergoing general anesthesia.
• Providing short-term skeletal muscle relaxation during outpatient or inpatient surgical procedures.
• Assisting mechanical ventilation and preventing spontaneous respiratory resistance during brief operative interventions.

Before Taking Mivacurium: Contraindications & Precautions

Because Mivacurium induces complete paralysis of respiratory muscles and relies on plasma cholinesterase for clearance, thorough patient screening before administration is mandatory.

Who Should Not Take Mivacurium?

Mivacurium is strictly contraindicated in patients with known hypersensitivity to Mivacurium chloride, bisbenzylisoquinolinium derivatives, or formulation components. It must never be administered to individuals with homozygous genetic plasma cholinesterase deficiency, as these patients experience prolonged, life-threatening paralysis. Patients without secure artificial airway management and full mechanical ventilatory support must not receive Mivacurium.

Mivacurium: Pregnancy & Fertility

Clinical safety studies regarding Mivacurium in pregnant women are limited, and it should be used during pregnancy only if the potential benefit justifies potential fetal risk. Mivacurium crosses the placenta in minimal amounts and is frequently used during cesarean delivery without causing fetal neuromuscular blockade. It is unknown whether Mivacurium is excreted in human milk, though systemic absorption by a nursing infant is unlikely. Animal studies demonstrate no evidence of impaired reproductive fertility.

Tell Your Doctor Before Taking Mivacurium

Inform your anesthesiologist if you or any family members have a history of atypical plasma cholinesterase levels or prolonged recovery from anesthesia. Disclose any existing cardiovascular conditions, high blood pressure, or history of severe allergies and asthma. Provide a complete list of all prescription drugs, eye drops, and over-the-counter medications currently in use.

Mivacurium: Dosage & Administration

Mivacurium is formulated as a clear 2 mg/mL sterile solution intended strictly for intravenous bolus injection or continuous infusion by trained anesthesia personnel.

• Intravenous Bolus Injection: Administered over 5 to 15 seconds to induce rapid muscle relaxation for intubation.
• Continuous Intravenous Infusion: Titrated carefully to maintain consistent, short-term neuromuscular blockade during longer surgeries.
• Peripheral Nerve Monitoring: Administered using a peripheral nerve stimulator to continuously assess muscle twitch response and recovery.

Standard Mivacurium Dosing

For adult patients under general anesthesia, the standard initial intravenous bolus dosage of Mivacurium is 0.15 mg/kg to 0.25 mg/kg administered over 5 to 15 seconds. This produces optimal intubation conditions within 2 to 2.5 minutes, with a total duration of neuromuscular blockade lasting roughly 15 to 20 minutes. For continuous maintenance, an intravenous infusion rate of 9 to 10 mcg/kg/min is initiated and titrated based on peripheral nerve stimulator responses. Pediatric doses are calculated based on age and body weight, typically requiring higher initial relative dosing due to faster plasma clearance.

How Mivacurium Is Administered

Mivacurium solution is inspected visually for clarity and injected directly into an active intravenous line by an anesthesiologist. To avoid rapid histamine release and transient blood pressure drops, high doses should be administered slowly over 60 seconds.

Mivacurium: Clinical Efficacy & Research

Established clinical consensus confirms that Mivacurium provides a rapid, predictable onset of non-depolarizing muscle relaxation with a significantly shorter duration of action than intermediate agents like vecuronium or rocuronium. Clinical trials demonstrate that spontaneous recovery of muscle strength occurs within 15 to 30 minutes following a standard bolus dose in individuals with normal plasma cholinesterase activity. Research highlights that Mivacurium is rapidly cleared by plasma pseudocholinesterase, allowing swift patient recovery and early discharge in ambulatory, day-surgery procedures.

Mivacurium: Side Effects & Safety Profile

Mivacurium exhibits a favorable safety profile, though its tendency to cause transient histamine release requires careful clinical management.

Common Mivacurium Side Effects

• Transient cutaneous flushing, erythema, and warmth of the face, neck, and chest
• Mild, temporary blood pressure drops (hypotension)
• Transient sinus tachycardia or minor heart rate increases
• Mild, temporary dizziness or localized vein irritation at the injection site

Serious Mivacurium Adverse Events

• Severe, prolonged neuromuscular blockade and prolonged apnea in patients with low or atypical plasma cholinesterase
• Severe, life-threatening anaphylactic or anaphylactoid reactions
• Severe, acute bronchospasm or wheezing, particularly in patients with reactive airway disease
• Marked hypotension and circulatory collapse secondary to rapid histamine release

Managing Mivacurium Side Effects

If prolonged neuromuscular blockade occurs, mechanical ventilation must be maintained continuously until full, spontaneous muscle strength returns or acetylcholinesterase inhibitors (neostigmine paired with atropine) are administered. If severe hypotension or bronchospasm develops, intravenous fluids, vasopressors, and antihistamines should be administered immediately.

Mivacurium: Interactions & What to Avoid

Combining Mivacurium with drugs that inhibit plasma cholinesterase or impair neuromuscular transmission enhances the depth and duration of muscle paralysis.

Mivacurium: Interactions

• Cholinesterase inhibitors (neostigmine, organophosphates, anticholinesterase eye drops): Inhibit plasma cholinesterase, paradoxically prolonging Mivacurium duration before spontaneous recovery begins.
• Inhalational anesthetics (isoflurane, sevoflurane, desflurane): Potentiate non-depolarizing neuromuscular blockade, requiring reduced Mivacurium infusion rates.
• Antibiotics (aminoglycosides, tetracyclines, polymyxins): Enhance neuromuscular blockade, increasing the risk of prolonged respiratory depression.

Mivacurium: Food & Alcohol

Dietary intake does not directly alter intravenous Mivacurium, though patients undergoing general anesthesia must follow strict pre-operative fasting rules. Alcohol consumption enhances central nervous system depression and can alter cardiovascular stability during anesthesia.

Mivacurium: Missed Dose, Overdose & Storage

Because Mivacurium is administered solely during controlled clinical procedures, routine patient self-administration rules do not apply.

Missed Dose of Mivacurium

Missed dose scenarios do not occur, as Mivacurium is administered on-demand as a single procedure-specific injection by healthcare providers.

Mivacurium: Overdose & Emergency

Mivacurium overdose leads to prolonged muscle paralysis, complete respiratory arrest, and severe hypotension. Emergency treatment requires continuous mechanical ventilation, airway maintenance, and administration of reversal agents like neostigmine paired with atropine once initial spontaneous recovery begins.

How To Store Mivacurium

Store Mivacurium injection solutions under refrigeration between 2°C and 8°C (36°F and 46°F) in their original carton to protect from light. Avoid freezing, and discard any unused portions remaining in opened vials immediately.

Mivacurium: Patient Management & Monitoring

Continuous electrophysiological and vital sign monitoring is mandatory whenever Mivacurium is administered.

Tests Before Starting Mivacurium

• Baseline evaluation of plasma cholinesterase activity in patients with a personal or family history of prolonged anesthesia recovery.
• Pre-anesthetic screening for cardiovascular stability, asthma, and underlying neuromuscular disorders.

Monitoring During Mivacurium Treatment

• Continuous monitoring of muscle twitch response using a peripheral nerve stimulator to evaluate paralysis depth and recovery.
• Continuous monitoring of blood pressure, heart rate, electrocardiogram (ECG), pulse oximetry, and end-tidal carbon dioxide.

Mivacurium: Do’s and Don’ts

• Do ensure complete mechanical ventilation support and resuscitation equipment are fully operational before administration.
• Do administer high bolus doses slowly over 60 seconds to minimize histamine-mediated flushing and hypotension.
• Don’t administer Mivacurium to patients known or suspected to have homozygous atypical plasma cholinesterase.
• Don’t attempt pharmacological reversal with neostigmine until early spontaneous twitch recovery is demonstrated.

Frequently Asked Questions

References

• United States Food and Drug Administration. Mivacron (Mivacurium Chloride Injection) Prescribing Information.
• DrugBank Online Database. Mivacurium Compound Summary (Accession Number DB01226).
• World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: M03AC10 (Mivacurium chloride).

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.